SXTP Stock Forecast & Price Target

60 Degrees Pharmaceuticals Inc. has demonstrated notable sales momentum, with full-year product revenues increasing to $1 million, a 67% rise from the previous year's $600,000, primarily driven by sustained growth in ARAKODA sales. The company's Q3 FY25 results reflect this trajectory, as net product revenue surged 223% year-over-year to $438,000, alongside a 14% increase in ARAKODA deliveries, indicating robust market demand. The upward revision of earnings per share estimates for FY26, driven by rising revenue projections, underscores the potential for continued financial improvement and market expansion, bolstered by a strategic partnership with a telehealth platform aimed at enhancing ARAKODA's accessibility.

60 Degrees Pharmaceuticals Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to low visibility on regulatory approvals for new indications, which raises concerns about the company's ability to progress its therapeutic pipeline. Financial results indicate continued losses, with Q4 FY25 EPS reported at $(2.05) against a revenue of only $0.3 million, highlighting a shortfall in financial performance compared to expectations. Furthermore, risks are compounded by potential dilution from capital raises, higher operating expenses, and an overall lack of investor confidence stemming from the company's inability to secure funding and deliver successful clinical trial outcomes.